Top Section/Ad
Top Section/Ad
Most recent
Dasha Sobornova joins from Akin Gump with experience across asset classes
Trade body for levfin investors turns to leading rating analyst
Demand for riskiest tranches and improved loan supply could support growth in issuance
Dana Point 'no longer the end' of the year as market retains momentum
More articles/Ad
More articles/Ad
More articles
-
CLO investors on Monday said that they were pleased with the decision by Valeant Pharmaceuticals to appoint Joseph Papa as CEO, adding to the good news in recent weeks as to the direction of the embattled Canadian drug company. -
Blackstone's GSO Debt Funds Management has scaled up its latest European CLO on the back of heavy demand from Japanese buyers, making it one of the biggest CLOs to be launched globally in the year to date.
-
One of the US CLO market’s biggest investors is leading a stampede of hefty international buyers to the European market for the first time for years. It could spark a rejuvenation of a market that has struggled for years, write David Bell and Graham Bippart.
-
CLO equity investors have been getting squeezed in recent weeks, as managers look to retain more of their own equity in order to comply with risk retention rules and to speed up pricing.
-
The second quarter has seen CLO arrangers pushing through a burst of new issuance on the back of improving sentiment in the market, but a shortage of assets might prove a limiting factor for the market.
-
The first in a wave US CLOs that have been marketing for several weeks priced on Thursday, with BlueMountain selling its first CLO of the year.
